ARS Pharmaceuticals (SPRY) Consolidated Net Income (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted Consolidated Net Income of -$95.9 million for Q1 2026, down 120.44% sequentially from -$43.5 million in Q4 2025, and down 156.94% YoY from $168.5 million in Q1 2025.
ARS Pharmaceuticals (SPRY) Consolidated Net Income (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Consolidated Net Income for 7 years, with the latest figure at -$95.9 million in Q1 2026.
- Quarterly Consolidated Net Income fell 156.94% year-over-year to -$95.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$474.7 million (down 122.98% YoY) and the FY2025 annual result came in at -$171.3 million, down 2241.76% from the prior year.
- Consolidated Net Income declined to -$95.9 million in Q1 2026 per SPRY's latest filing, from -$43.5 million in the prior quarter.
- Over five years, Consolidated Net Income peaked at $47.3 million in Q4 2024 and troughed at -$39.4 billion in Q1 2023.
- A 5-year average of -$5.5 billion and a median of -$67.4 million in 2024 frame the typical range for Consolidated Net Income.
- The sharpest annual moves came in 2023 and 2024: Consolidated Net Income plunged 339646.93% in 2023, then jumped 571.87% in 2024.
- Over 5 years, Consolidated Net Income stood at -$15.1 million in 2022, then jumped by 33.83% to -$10.0 million in 2023, then surged by 571.87% to $47.3 million in 2024, then sank by 192.08% to -$43.5 million in 2025, then tumbled by 120.44% to -$95.9 million in 2026.
- According to Business Quant data, Consolidated Net Income over the past three periods registered -$95.9 million, -$43.5 million, and -$113.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | -96.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -96.68 Mn |
| Mar 31, 2026 | -95.93 Mn |
| Dec 31, 2025 | -43.52 Mn |
| Sep 30, 2025 | -112.98 Mn |
| Jun 30, 2025 | -222.27 Mn |
| Mar 31, 2025 | -37.34 Mn |
| Dec 31, 2024 | 47.26 Mn |
| Sep 30, 2024 | -155.41 Mn |
| Jun 30, 2024 | -67.41 Mn |
| Mar 31, 2024 | -90.90 Mn |
| Dec 31, 2023 | -10.02 Mn |
| Sep 30, 2023 | -15.46 Bn |
| Jun 30, 2023 | -38.20 Bn |
| Mar 31, 2023 | -39.41 Bn |
| Dec 31, 2022 | -15.14 Mn |
| Sep 30, 2022 | -15.16 Mn |
| Jun 30, 2022 | -13.54 Mn |
| Mar 31, 2022 | -11.60 Mn |
| Dec 31, 2021 | 47.19 Mn |
| Sep 30, 2021 | -44.42 Mn |